Secukinumab As A More Efficient Alternative For The Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis Versus Adalimumab And Golimumab From A Colombian Perspective
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.887
https://www.valueinhealthjournal.com/article/S1098-3015(17)31221-4/fulltext
Section Title :
Disease-Specific Studies
Section Order :
846
First Page :
A555
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31221-4&doi=10.1016/j.jval.2017.08.887